the role of ibrutinib in the frontline treatment of young patients with cll
Published 1 year ago • 225 plays • Length 2:06Download video MP4
Download video MP3
Similar videos
-
3:46
the characteristics and mode of action of ibrutinib for cll
-
2:07
efficacy of ibrutinib in the treatment of cll patients with del(17p) and tp53 mutation
-
1:44
the impact of acalabrutinib treatment by line of therapy in patients with cll
-
1:31
can ibrutinib be used as a first-line treatment in cll?
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
33:01
thriving with cll: what you should know about care and treatment
-
5:29
long term follow-up with ibrutinib venetoclax to treat chronic lymphocytic leukemia
-
7:24
what are the current cll treatment options?
-
1:36
cll2-give trial: ibrutinib, venetoclax and obinutuzumab in patients with tp53-mutated cll
-
2:14
ibrutinib's role in cll treatment and future outlooks
-
2:55
audio described: clinical trial tests nivolumab for patients with rare brain and spine cancers
-
1:47
ianalumab add-on therapy in cll patients receiving ibrutinib
-
1:15
the current role of acalabrutinib in the treatment of cll
-
1:05
long-term outcomes of patients with cll treated with continuous ibrutinib
-
1:42
ibrutinib and fcr chemoimmunotherapy: improving complete remission in cll patients?
-
3:48
ibrutinib in treatment for refractory or relapsed cll
-
2:01
all things ibrutinib and cll
-
2:55
clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
-
2:18
first-line ibrutinib and venetoclax in cll
-
1:05
final analysis of the alpine trial: zanubrutinib vs ibrutinib in r/r cll
-
2:57
the cll12 trial of ibrutinib in early stage cll
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients